Keryx Biopharma To Change CEO Role From Ron Bentsur To Greg Madison

(RTTNews) - Keryx Biopharmaceuticals Inc. (KERX) announced it will be transitioning the role of Chief Executive Officer from Ron Bentsur to its current Chief Operating Officer, Greg Madison.

Bentsur has led Keryx for the past 5 years, culminating in U.S. Food and Drug Administration approval and year-end 2014 launch of Auryxia (ferric citrate).

Madison joined Keryx in February 2014 as Chief Operating Officer to transition the Company from a development-stage organization into a fully integrated commercial entity, bringing to Keryx a wealth of relevant expertise in both the phosphate binder and iron deficiency anemia markets. Madison has been appointed President of Keryx and will work with Bentsur to ensure a successful leadership transition by the end of May, when Bentsur's contract expires.

Prior to joining Keryx, Madison served as the Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals where he led the team to significant growth in net revenues. Prior to AMAG, Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division.

In this role, Madison led a global organization with three marketed products with combined revenues exceeding $1 billion. Madison's prior experience in the Renal division included serving as Vice President and General Manager of the U.S. business; Vice President of U.S. sales; and Vice President of U.S. marketing where he led all pre-launch preparation for Renvela.